NCT01392495View on ClinicalTrials.gov

Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)

PHASE3TerminatedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

Imatinib

200 mg or 400 mg qd

Trial Locations (7)

2010

Novartis Investigative Site, Darlinghurst

3000

Novartis Investigative Site, Leuven

11501

Novartis Investigative Site, Mineola

30625

Novartis Investigative Site, Hanover

00161

Novartis Investigative Site, Roma

LT-08661

Novartis Investigative Site, Vilnius

NW3 2QG

Novartis Investigative Site, London

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY